5 year Survival rate of progesterone level changes on the Her 2 Over Expression Breast Cancer Progressivity in Single Center Hospital

ABSTRACT

Introduction: Breast cancer is a serious health problem for women worldwide. Incidence and death rates are increasing rapidly. According to GLOBOCAN 2020, breast cancer is the most frequently diagnosed and the leading cause of cancer-related deaths. Most breast tumors express nuclear estrogen receptor (ER) and progesterone receptors (PR) early in the disease and as they progress. Characterization of tumor growth factor receptor status ER, PR, and HER2. These markers can be used to define tumor functional groups: hormone receptor positive, HER2-negative; hormone receptor negative, HER2-negative ('Triple negative” tumors), and HER2 overexpression.

Methods: An observational quantitative study using a prospective cohort. With a sample of HER2 overexpression breast cancer patients, our study was conducted over 5 years (from 2015 to 2021) in a single center hospital. Analysis was done on the 5-year survival rate from the influence of risk factors and progesterone levels on the progression of HER2 overexpression in breast cancer patients.

Results: The total sample was 51 patients, 29 patients were excluded because of patient mortality, with an overall survival rate of 56.86%. The results show an effect on the level of progesterone in the blood with the progression of HER2 overexpression breast cancer, with a p value = 0.39. There was no effect from the analyzed risk factors on the progression of HER2 overexpression of breast cancer.

Conclusion: The 5-year survival rate of patients with HER2 overexpression breast cancer is 56.86%, with progesterone levels influencing the progression of HER2 overexpression breast cancer with p= 0.038